NCT05493995 - A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 21, 2022

Primary Completion Date

May 1, 2024

Study Completion Date

May 1, 2024

Conditions

Pancreatic Neoplasms

Interventions

DRUG

Penpulimab

Penpulimab 200 mg administered intravenously every 3 weeks.

DRUG

Anlotinib

12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.

DRUG

Nab paclitaxel

125mg/m\^2，administered intravenously on days 1 and 8 of every 21-day cycle.

DRUG

Gemcitabine

1.0g/m\^2, administered intravenously on days 1 and 8 of every 21-day cycle.

Trial Locations (1)

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing